UK MHRA "Path to market" could be code for price negotiations.
$4,000 course if treatment could be too expensive for mild/moderate patients???
Its also tricky for CYDY as they must set a price that will work for severe/critical as well.
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-